RT Journal Article
SR Electronic
T1 Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.25.22269794
DO 10.1101/2022.01.25.22269794
A1 Servellita, Venice
A1 Syed, Abdullah M.
A1 Brazer, Noah
A1 Saldhi, Prachi
A1 Garcia-Knight, Miguel
A1 Sreekumar, Bharath
A1 Khalid, Mir M.
A1 Ciling, Alison
A1 Chen, Pei-Yi
A1 Kumar, G. Renuka
A1 Gliwa, Amelia S.
A1 Nguyen, Jenny
A1 Sotomayor-Gonzalez, Alicia
A1 Zhang, Yueyuan
A1 Frias, Edwin
A1 Prostko, John
A1 Hackett, John
A1 Andino, Raul
A1 Doudna, Jennifer
A1 Ott, Melanie
A1 Chiu, Charles Y.
YR 2022
UL http://medrxiv.org/content/early/2022/01/26/2022.01.25.22269794.abstract
AB Virus-like particle (VLP) and live virus assays were used to investigate neutralizing immunity to Delta and Omicron SARS-CoV-2 variants in 239 samples from 125 fully vaccinated individuals. In uninfected, non-boosted individuals, VLP neutralization titers to Delta and Omicron were reduced 2.7-fold and 15.4-fold, respectively, compared to wild-type (WT), while boosted individuals (n=23) had 18-fold increased titers. Delta breakthrough infections (n=39) had 57-fold and 3.1-fold titers whereas Omicron breakthrough infections (n=14) had 5.8-fold and 0.32-fold titers compared to uninfected non-boosted and boosted individuals, respectively. The difference in titers (p=0.049) was related to a higher proportion of moderate to severe infections in the Delta cohort (p=0.014). Correlation of neutralizing and spike quantitative antibody titers was decreased with Delta or Omicron compared to WT. Neutralizing antibodies in Delta and Omicron breakthrough infections increase overall, but the relative magnitude of increase is greater in more clinically severe infection and against the specific infecting variant.Competing Interest StatementC.Y.C. is the director of the UCSF-Abbott Viral Diagnostics and Discovery and receives research support for SARS-CoV-2 studies from Abbott Laboratories. The other authors declare no competing interests.Funding StatementThis work was funded by US CDC Epidemiology and Laboratory Capacity (ELC) for Infectious Diseases Grant 6NU50CK000539 to the California Department of Public Health (COVIDnet) (M-K.M., C.H., D.A.W., C.Y.C.), the Innovative Genomics Institute (IGI) at UC Berkeley and UC San Francisco (J.D., M.O., C.Y.C.), US Centers for Disease Control and Prevention contract 75D30121C10991 (C.Y.C.), the Roddenberry Foundation (M.O.), National Institutes of Health (NIH) grants R37AI083139 (M.O.), R21AI59666 (J.A.D.), and U54HL147127 (M.M.K.), the Howard Hughes Medical Institute (J.A.D.), the Gladstone Institutes (J.A.D. and M.O.), Abbott Laboratories (C.Y.C.), and the Sandler Program for Breakthrough Biomedical Research (C.Y.C.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The findings and conclusions in this article are those of the author(s) and do not necessarily represent the views or opinions of the California Department of Public Health or the California Health and Human Services Agency.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of UCSF gave ethical approval for this work Details in manuscript: Blood samples were collected through two methods. First, remnant whole blood and plasma samples from patients hospitalized with COVID-19 at UCSF were retrieved from UCSF Clinical Laboratories daily based on availability. Remnant samples were biobanked and retrospective medical chart reviews for relevant demographic and clinical metadata were performed under a waiver of consent and according to protocols approved by the UCSF Institutional Review Board (protocol numbers 10-01116 and 11-05519). Samples were obtained from pediatric and adult patients of all genders. No analyses based on sex or age were conducted. Second, plasma samples were also collected through the UMPIRE (UCSF EMPloyee and community member Immune REsponse) study, a longitudinal COVID-19 research study focused on collection of prospective whole blood and plasma samples from enrolled subjects to evaluate the immune response to vaccination, with and without boosting, and/or vaccine breakthrough infection. Informed consent for participation in the UMPIRE study and collection of data and samples were obtained according to a protocol approved by the UCSF Institutional Review Board (protocol number 20-33083).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.